New research has shed light on why immune checkpoint blockade immunotherapy does not always work in some cancers with a high tumor mutational burden. The...
Two Phase III biotechs will join the Nasdaq Friday morning, with radiopharma startup RayzeBio and brain disease drug developer Neumora raising $311 million...
Recommendations from the Standards for Human Stem Cell Use in Research, published in June by the International Society for Stem Cell Research (ISSCR),...
A new study has shed light on why immunotherapy does not always work in certain types of cancer. Led by researchers at EMBL’s European Bioinformatics...
New company AlveoGene, backed by experts at the UK Respiratory Gene Therapy Consortium (GTC), has made its debut with a lead program for rare respiratory...
Credit: Insilico Medicine ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine’s...
BIRMINGHAM, Ala. – In the summer of 2018, graduate student Hunter Dean from the Medical Scientist Training Program came to Yuhua Song, Ph.D., with a...
Researchers have invented a nano-thin superbug-slaying material that could one day be integrated into wound dressings and implants to prevent or heal bacterial...
The discovery of a previously unknown molecular target has inspired what may become a therapeutic breakthrough for people with glioblastoma, the most common...
A Deeper Dive Into The Role Of Spike Protein In Myocarditis And Blood Clotting After COVID-19 Vaccination Authored by Allison Kruig, MPH and...
Developing new drugs is paramount in discovering innovative treatments and preventing diseases. This is vital not only for advancing medicine but also...
A few days after the launch of Superluminal Medicines was announced on August 28, CEO Cony D'Cruz told GEN about the company's journey, which started as...
When Richard O’Neil, Ph.D., joined MUSC Hollings Cancer Center two years ago, he knew that he wanted to continue finding ways to make CAR-T-cell therapy...
Despite advances in developing radiopharmaceuticals, manufacturing such drugs remains a challenge. One startup’s plan to tackle the issue is beginning...
Biogen has appointed Jane Grogan as its new head of research. The move comes after CEO Chris Viehbacher said earlier this year he would split up...
PITTSBURGH – To reimagine existing preclinical trials for Alzheimer’s disease, University of Pittsburgh School of Medicine neuroscientists created...
Welcome to TDR’s review of the Top 5 Psychedelic Developments for the week of August 28. Aside from presenting a synopsis of events, we provide market...
Canadian next-generation psychedelics developer Mindset Pharma MSSTF has entered into a definitive agreement by which Otsuka America Inc., the U.S....
From Cambridge, U.K., to Cambridge, MA, and from creating better cytokines to aiding gene therapy, the development of new amino acids is likely to open...
David Khougazian It’s a classic biopharma story. In January, David Khougazian bumped into Flagship Pioneering founder Noubar Afeyan at the JP Morgan...
Canadian next-generation psychedelics developer Mindset Pharma MSSTF has entered into a definitive agreement by which Otsuka America Inc., the U.S....
Zevra Therapeutics is set to buy Acer Therapeutics in a deal worth up to $91 million, which finds the Florida-headquartered biotech with an additional...
Developing new drugs to combat these infectious diseases is crucial, but the process is fraught with challenges. One major obstacle is the selection of...
The surface protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), known as the spike protein, is critical for infecting host cells....
Eli Lilly completed its acquisition of antibody-drug conjugate biotech Emergence Therapeutics, the Indianapolis pharma company confirmed to Endpoints News...
Apellis said its field-based commercial and medical employees would be “minimally affected,” and that the job cuts will be “substantially” completed...
A pair of late-stage biotechs submitted IPO plans last week as industry insiders gear up for what could be a handful of post-Labor Day public debut...
Findings from the Garvan Institute of Medical Research reveal a new Australian drug that targets scar-like ‘fibrotic’ tissue within tumours shows promise...
Though drug developers have achieved some progress in treating Alzheimer’s disease with medicines that reduce amyloid-beta protein, other problems of...
Apellis Pharmaceuticals is in cash-saving mode as it looks to ward off a newly-minted competitor in treating a leading cause of blindness. The drugmaker...